AI and Super-Fast Followers: Is the Patent Bargain Breaking Down?
1 hr 0 min
Send us Fan Mail This week on IPWatchdog Unleashed, our host and the founder of IPWatchdog, Gene Quinn, speaks with Emily Johnson, Nicholas Lanzatella, Kwame Mensah, and Corey Salsberg. The panel explores how artificial intelligence is reshaping life sciences R&D and enabling “super-fast followers” to build rapidly on publicly disclosed pharmaceutical research. At stake is the balance between accelerating the development of new medicines and preserving the economic incentives that make pioneering discoveries possible. The discussion examines whether AI-assisted patent scraping threatens the patent bargain or accelerates the follow-on innovation the system is designed to encourage. The panel debates the difficulty of securing broad patent protection after Amgen v. Sanofi, the role of Section 112’s enablement and written description requirements, and how increasingly capable AI tools could affect obviousness and human inventorship. Throughout, the speakers distinguish legitimate competitive advances from unsupported filings and question whether proposed policy responses could undermine innovators’ own use of AI. A central takeaway is to become your own fast follower: use AI to anticipate competing variants, strengthen supporting disclosures, and pursue further innovation before competitors capitalize on published research. The conversation highlights the value of documenting human conception, developing evidence of unexpected results, and aligning patent strategy with the science needed to support meaningful claim scope. It is a timely examination of how innovators can protect research investment while harnessing the technology that is changing the competitive landscape. Visit us online at IPWatchdog.com. You can also visit our channels at YouTube, LinkedIn, X, Instagram and Facebook.